Drug Discovery and Development

At Incyte, our therapeutic focus is primarily oncology. Since we began our drug discovery and development activities in early 2002, we have filed Investigational New Drug (IND) applications and progressed multiple internally developed proprietary compounds into clinical development. In late 2011, we received our first US Food and Drug Administration approval for Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor.

Incyte has an exceptional team of drug discovery and development scientists, led by distinguished executives with proven records of success and many scientific and clinical achievements. We employ only the best and those who adhere to the highest standards of scientific and clinical rigor, and we resource our programs for success. We have a strong discovery team that is tightly integrated with all disciplines, including development, regulatory, and commercial operations. 

Pivotal Science

Our scientific innovation is based on a proven competency in medicinal chemistry, which is seamlessly integrated into a discovery process that is tailored to individual program needs. We have expanded our drug identification efforts to include large molecules, which enables us to access a broad range of cancer drug targets. We continually modify the resourcing of our discovery efforts to maximize information content when and where we need it and ensure that each program, regardless of stage, is executed in the most efficient and data-rich manner possible. 

It’s not enough just to be smart. We look to our colleagues to be as creative as they are critical in their thinking

— Wenqing Yao, Executive Vice President, Discovery Chemistry